Background Cardiovascular disease remains the leading cause of death worldwide, resulting in an increasing demand for long-term treatment options for patients with end-stage heart failure. While heart transplantation is the gold standard, donor organ shortage continues to be a major limitation, particularly in countries with opt-in consent systems. Summary Durable mechanical circulatory support (dMCS) devices have emerged as a critical therapy for patients with advanced heart failure, either as a bridge to transplantation or as destination therapy. Technological innovations over recent decades have transitioned from pulsatile to continuous-flow systems, with the HeartMate 3 currently representing the only long-term left ventricular support, due to its superior hemocompatibility, clinical outcomes, and full magnetic levitation. However, limitations persist, especially regarding right-sided and biventricular support, driveline infections, and patient quality of life. This review provides a comprehensive overview of both currently approved and investigational dMCS devices, highlighting key engineering features, hemocompatibility advancements, and the status of ongoing clinical trials. Emerging devices such as the Corheart 6, BrioVAD, EvaHeart 2, CorWave, FlowMaker, and TorVAD aim to enhance physiologic support, minimize shear stress, and enable full implantability. Additionally, novel concepts for biventricular and total heart replacement, including BerlinHeart Excor, reBEAT, DuoCor BiVAS, SynCardia, Emperor and BiVACOR are discussed. Key Messages •HeartMate 3 remains the only approved LVAD in Europe following HVAD withdrawal. •Next-generation devices aim to improve hemocompatibility, reduce complications, and support full implantability. •Options for biventricular or right heart failure remain limited, but novel concepts are emerging.

The article "Exploring an Alternative Preoperative Sentinel Lymph Node Mapping Method Using a Magnetic Tracer and Magnetic Resonance Imaging for Melanoma Patients: SCARLETT Study Protocol" [Eur Surg Res 2026;67:30-37; https://doi.org/10.1159/000549828] by Aldenhoven et al. was published with the wrong open access license. The correct license of the article is CC-BY.The original article has been updated.

The article "Simultaneous Liver-Kidney Transplantation versus Liver Transplantation in End-Stage Liver Disease Patients with Kidney Dysfunction" [Eur Surg Res. 2026;67:46-55; https://doi.org/10.1159/000550008] by Bouari et al. was published with the wrong open access license. The correct license of the article is CC-BY.The original article has been updated.

The article "Desensitization Strategies in Immunized Heart Transplant Recipients" [Eur Surg Res. 2026;67:1-9; https://doi.org/10.1159/000549669] by Goerler et al. was published with the wrong open access license. The correct license of the article is CC-BY.The original article has been updated.

The authors' accepted manuscript "Is Methylene Blue a Reliable Substitute in Sentinel Lymph Node Biopsy? A Systematic Review across Oncologic Sites" [Eur Surg Res. 2025; https://doi.org/10.1159/000549037] by Saurabh Raj, Rudrakshi Mahaldar, and Shahrukh Memon has been retracted by the Publisher and the Editor on the authors' behalf.After peer review, the accepted, unedited manuscript was published online as Early View. Before the final Version of Record was published, concerns were raised about the validity of references 4, 6, 7, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, 23, 24, 25, 40 and 41 of the manuscript.The corresponding author stated that errors arose due to their use of AI-assisted tools and requested that their manuscript be withdrawn from European Surgical Research. Consequently, the published author's accepted manuscript has been retracted.Saurabh Raj agrees to this retraction, Rudrakshi Mahaldar and Shahrukh Memon have not responded to our correspondence about this retraction.